ArticleFrontiers in medicine2025
Exploration of factors influencing pulmonary injury in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis and construction of a predictive model.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A bad prognosis results from pulmonary involvement of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). A method for early detection of AAV patients at risk of developing pulmonary involvement is still required, despite the existence of predictive models for death. The purpose of this study was to determine risk factors and develop a predictive model for pulmonary involvement in AAV. Methods: Seventy-one treatment-naïve AAV patients (38 with pulmonary involvement) participated in a retrospective cross-sectional investigation. To choose predictors and create a nomogram, multivariate logistic regression and the least absolute shrinkage and selection operator (LASSO) were employed. Receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA) with a 7:3 training-to-validation split were used to assess the model. Results: Four independent predictors were identified: intermittent symptom pattern (OR = 8.52, 95% CI: 2.17-33.46), limb numbness/paresthesia (OR = 12.21, 95% CI: 1.98-75.50), older age at onset (OR = 1.05 per year, 95% CI: 1.01-1.10), and lower hemoglobin level (OR = 0.97 per g/L, 95% CI: 0.95-0.99). A nomogram incorporating these factors demonstrated good discrimination, with an area under the curve (AUC) of 0.88 (95% CI: 0.77-0.98) in the training set and 0.83 (95% CI: 0.64-1.00) in the validation set. Calibration and decision curve analysis confirmed the model's clinical utility. Conclusion: Using standard clinical markers, we created and internally verified a pragmatic prediction model for pulmonary involvement in AAV. Personalized monitoring and early risk categorization may benefit from this approach. To verify its generalizability, external validation in prospective, multi-center cohorts is advised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.